SB Investment Advisers UK Ltd. Trims Stock Holdings in Roivant Sciences Ltd. $ROIV

SB Investment Advisers UK Ltd. cut its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 83.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,671,732 shares of the company’s stock after selling 13,741,871 shares during the period. Roivant Sciences comprises approximately 1.0% of SB Investment Advisers UK Ltd.’s holdings, making the stock its 7th biggest position. SB Investment Advisers UK Ltd.’s holdings in Roivant Sciences were worth $74,007,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ROIV. Morgan Stanley raised its stake in Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after acquiring an additional 14,036,696 shares during the period. Vanguard Group Inc. boosted its stake in Roivant Sciences by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after acquiring an additional 3,254,113 shares during the period. Rubric Capital Management LP grew its holdings in shares of Roivant Sciences by 14.7% during the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the last quarter. State Street Corp grew its holdings in shares of Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after purchasing an additional 911,827 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after purchasing an additional 15,645,836 shares during the period. Institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In related news, Director Daniel Allen Gold sold 12,380 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the sale, the director owned 13,689,166 shares of the company’s stock, valued at $482,953,776.48. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. This trade represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,855,913 shares of company stock valued at $62,649,633. Company insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Citigroup boosted their price objective on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Guggenheim increased their target price on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, HC Wainwright restated a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Trading Down 2.5%

Roivant Sciences stock opened at $33.84 on Wednesday. The stock has a market cap of $24.34 billion, a price-to-earnings ratio of -56.40 and a beta of 1.11. The company’s 50-day moving average price is $32.47 and its two-hundred day moving average price is $28.85. Roivant Sciences Ltd. has a 52 week low of $10.90 and a 52 week high of $37.00.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.